Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation Ready to Announce with Confidence?

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws.

On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026.

Management noted that the transition from its current TDAPA for DefenCath was expected to significantly reduce institutional reimbursement levels and net pricing in the second half of 2026.

As a result, CorMedix lowered its full year revenue guidance from $400M down to $300M - $320M.

Following this news, CRMD's stock price fell over 21% to open at $8.73 per share.

If you suffered a loss on your CorMedix Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212)363-7500

Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280354

Source: Levi & Korsinsky, LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.

Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation

2026-01-14 9:58 AM EST

Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST)

2026-01-14 9:55 AM EST

Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors

2026-01-14 9:51 AM EST

May 29, 2025

When your company’s earnings news hits the market, stock prices can react in milliseconds. A 2025 UC San Diego study analyzing over 89...

Economy, Business and Finance

Legal Service

Litigation and Regulation

Banking / Financial Services